Veli Berk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10464197/publications.pdf

Version: 2024-02-01

933264 24 622 10 citations h-index papers

g-index 24 24 24 1066 docs citations all docs times ranked citing authors

1058333

14

#	Article	IF	CITATIONS
1	Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. International Journal of Cardiology, 2013, 167, 2306-2310.	0.8	258
2	Protective effects of spironolactone against anthracyclineâ€induced cardiomyopathy. European Journal of Heart Failure, 2015, 17, 81-89.	2.9	172
3	Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Medical Oncology, 2014, 31, 801.	1.2	52
4	Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). Journal of Chemotherapy, 2014, 26, 300-305.	0.7	26
5	Adjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Cancer. Oncology, 2013, 84, 14-21.	0.9	22
6	Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Onkologie, 2012, 35, 740-745.	1.1	19
7	Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection. Clinical Colorectal Cancer, 2017, 16, 220-227.	1.0	18
8	Haematologic Parameters in Metastatic Colorectal Cancer Patients Treated with Capecitabine Combination Therapy. Asian Pacific Journal of Cancer Prevention, 2014, 15, 253-256.	0.5	14
9	Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Medical Oncology, 2012, 29, 3119-3124.	1.2	12
10	Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?. Clinical Genitourinary Cancer, 2015, 13, 548-554.	0.9	10
11	Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thoracic Cancer, 2014, 5, 398-404.	0.8	6
12	Lack of Prognostic Value of Mean Corpuscular Volume with Capecitabine Therapy in Metastatic Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2501-2504.	0.5	6
13	Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO). Anticancer Research, 2014, 34, 4463-70.	0.5	5
14	Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 408-16.	0.7	2
15	Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology). Wspolczesna Onkologia, 2015, 2, 125-129.	0.7	0
16	Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer Journal of Clinical Oncology, 2013, 31, e14533-e14533.	0.8	0
17	Predictive significance of VEGF and HIF- $1\hat{l}\pm$ expression in metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab Journal of Clinical Oncology, 2013, 31, e14672-e14672.	0.8	O
18	The relation between neutrophil lymphocyte ratio and survival in patients with small cell lung cancer Journal of Clinical Oncology, 2013, 31, e18516-e18516.	0.8	0

#	Article	IF	CITATIONS
19	Use of VEGF expression to predict for first-line treatment chemotherapy regimen in metastatic colorectal cancer Journal of Clinical Oncology, 2013, 31, e14695-e14695.	0.8	O
20	The efficacy and safety of first-line and salvage therapies with bevacizumab combination chemotherapy regimens in metastatic colorectal cancer: A retrospective ASMO experience Journal of Clinical Oncology, 2013, 31, e14705-e14705.	0.8	0
21	The effect of oral Î ² -glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy Journal of Clinical Oncology, 2013, 31, e20603-e20603.	0.8	O
22	Efficacy and safety results of pemetrexed administration in non-small cell lung cancers, a multicenter study of the Association of Anatolian Medical Oncology. Journal of Clinical Oncology, 2013, 31, e19107-e19107.	0.8	0
23	Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?. Journal of Clinical Oncology, 2015, 33, e15624-e15624.	0.8	O
24	Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in GEP-NETs Journal of Clinical Oncology, 2016, 34, e15646-e15646.	0.8	0